

PROVIDER BULLETIN

PROVIDER INFORMATION



April 2, 2018

Updated: New Medical Drug Prior Authorization Requirements for Voretigene Neparvovec (Luxturna™)

The information in this Bulletin provides an update to Provider Bulletin P2-18, which was published on January 11, 2018. The new information that has been added is the Medical Drug PA requirement for Voretigene Neparvovec (Luxturna™) using Medical Policy II-188.

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) expanded the Medical Drug Prior Authorization (PA) Program for Commercial and Government lines of business to include PA requirements for Voretigene Neparvovec (Luxturna™), on February 26, 2018.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring they receive the highest quality, evidence based care. One method for doing so is through the PA process. The primary purpose of the PA process is to ensure that evidence based care is provided to our subscribers, driving quality, safety, and affordability.

The criteria for approval of Voretigene Neparvovec (Luxturna™) is based on FDA approved product labeling (see medical policy II-173).

Updated: As of June 4, 2018, a Medical Drug PA will be required for Voretigene Neparvovec (Luxturna™) using Medical Policy II-188.

Products Impacted

- This PA program applies to subscribers that have coverage through all Commercial and the following Government programs; Prepaid Medical Assistance Program (PMAP), MinnesotaCare (MNCare), SecureBlue (MSHO), and Minnesota Senior Care Plus (MSC+) health plans.
- The changes do not impact Federal Employee Program (FEP), Medicare Supplement (Senior Gold, Basic Medicare Blue and Extended Basic Blue), Medicare Advantage or Platinum Blue as those lines of business have separate PA requirements.

Submitting a Medical Drug PA Request

Before submitting a PA request, Providers are asked to check applicable Blue Cross, MHCP and/or Medicare criteria and **attach all required clinical documentation** with the request including documentation of previous therapies tried and evidence of symptom improvement using the drug. PA requests will be reviewed when patient-specific, relevant medical documentation has been provided supporting the medical necessity of the drug. Failure to submit required information may result in review delays (if outreach is needed to obtain missing clinical information) or a denial of the request due to insufficient information. If a provider does not obtain the required PA before rendering services, Blue Cross will deny claims as provider liability for lack of prior authorization.

To review the Blue Cross and Medicare criteria:

- Go to providers.bluecrossmn.com
- Under Tools and Resources, select “Medical Policy”, then acknowledge the Acceptance statement
- Select the “+” (plus) sign next to Medical and Behavioral Health Policies

Continued on back

Bulletin P2R1-18

Distribution: All participating providers impacted by the information in this bulletin. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L08R04 (12/13)

Providers can submit an electronic medical drug prior authorization (ePA) request:

- Online via our free [Availity](#) provider portal – for Blue Cross to review
- Using a [NCPDP](#) standard XML file feed to Blue Cross through CenterX, via an integrated Electronic Medical Record (EMR) system. To learn how to do this, providers should contact their EMR vendor for assistance.
- Using the appropriate Government Program pre-authorization/pre-certification form available online at providers.bluecrossmn.com under the “Forms and Publications” section.
- Out of state, non-contracted providers can submit a PA request to Blue Cross by either using the electronic processes above, the [Minnesota Uniform Form for PA Request and Formulary Exceptions](#) fax form located under the Forms section on the Blue Cross website, or their own PA form (secure fax: 651.662.2810).

Note: An approved PA does not guarantee a medication is covered under a subscriber’s benefit plan. Subscriber benefit plans vary in coverage and some plans may not provide coverage for certain services discussed in the medical policies.

Reminder Regarding Medical Policy Updates and Changes

Medical Policy changes are communicated in the Upcoming Medical Policy Notifications section of the Blue Cross Medical and Behavioral Health Policy website. The Upcoming Policies section lists new, revised, or inactivated policies approved by the Blue Cross Medical and Behavioral Health Policy Committee and are effective 50 days from the date they were posted. To access the website:

- Go to providers.bluecrossmn.com
- Under Tools & Resources, select “Medical Policy”, and read/accept the Blue Cross Medical Policy Statement
- Select the “+” (plus) sign next to “Medical and Behavioral Health Policies” to see the Upcoming Medical Policy Notifications section

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.